BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16047184)

  • 1. Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense.
    Bauer D; Lu M; Wasmuth S; Li H; Yang Y; Roggendorf M; Steuhl KP; Heiligenhaus A
    Graefes Arch Clin Exp Ophthalmol; 2006 Feb; 244(2):216-25. PubMed ID: 16047184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctival macrophage-mediated influence of the local and systemic immune response after corneal herpes simplex virus-1 infection.
    Bauer D; Schmitz A; Van Rooijen N; Steuhl KP; Heiligenhaus A
    Immunology; 2002 Sep; 107(1):118-28. PubMed ID: 12225370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
    Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines.
    Heiligenhaus A; Li H; Schmitz A; Wasmuth S; Bauer D
    Clin Exp Immunol; 2005 Oct; 142(1):180-7. PubMed ID: 16178874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A crucial role for B and T lymphocyte attenuator in preventing the development of CD4+ T cell-mediated herpetic stromal keratitis.
    Xia L; Zhang S; Zhou J; Li Y
    Mol Vis; 2010 Oct; 16():2071-83. PubMed ID: 21042564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: implications for the role of neutrophils in HSK.
    Duan R; Remeijer L; van Dun JM; Osterhaus AD; Verjans GM
    Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):277-84. PubMed ID: 17197544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical administration of HSV gD-IL-2 DNA is highly protective against murine herpetic stromal keratitis.
    Inoue T; Inoue Y; Hayashi K; Yoshida A; Nishida K; Shimomura Y; Fujisawa Y; Aono A; Tano Y
    Cornea; 2002 Jan; 21(1):106-10. PubMed ID: 11805518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic keratitis.
    Inoue T; Inoue Y; Hayashi K; Shimomura Y; Fujisawa Y; Aono A; Tano Y
    Cornea; 2002 Oct; 21(7 Suppl):S79-85. PubMed ID: 12484704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical antisense-oligonucleotides targeting IFN-gamma mRNA improve incidence and severity of herpetic stromal keratitis by cytokine specific and sequence unspecific effects.
    Wasmuth S; Bauer D; Steuhl KP; Heiligenhaus A
    Graefes Arch Clin Exp Ophthalmol; 2008 Mar; 246(3):443-51. PubMed ID: 18030487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amniotic membrane transplantation induces apoptosis in T lymphocytes in murine corneas with experimental herpetic stromal keratitis.
    Bauer D; Wasmuth S; Hennig M; Baehler H; Steuhl KP; Heiligenhaus A
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3188-98. PubMed ID: 19255156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment with antisense oligonucleotides targeting tumor necrosis factor-alpha in herpetic stromal keratitis.
    Wasmuth S; Bauer D; Yang Y; Steuhl KP; Heiligenhaus A
    Invest Ophthalmol Vis Sci; 2003 Dec; 44(12):5228-34. PubMed ID: 14638721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1.
    Tumpey TM; Elner VM; Chen SH; Oakes JE; Lausch RN
    J Immunol; 1994 Sep; 153(5):2258-65. PubMed ID: 8051423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Suppression effects of interleukin-10 on mouse herpetic stromal keratitis].
    Xia LK; Gao DW; Pu W; Zhang JS
    Zhonghua Yan Ke Za Zhi; 2003 Oct; 39(10):592-6. PubMed ID: 14766072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis.
    Inoue T; Inoue Y; Nakamura T; Yoshida A; Inoue Y; Tano Y; Shimomura Y; Fujisawa Y; Aono A; Hayashi K
    Jpn J Ophthalmol; 2002; 46(4):370-76. PubMed ID: 12225814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody.
    Krawczyk A; Dirks M; Kasper M; Buch A; Dittmer U; Giebel B; Wildschütz L; Busch M; Goergens A; Schneweis KE; Eis-Hübinger AM; Sodeik B; Heiligenhaus A; Roggendorf M; Bauer D
    PLoS One; 2015; 10(1):e0116800. PubMed ID: 25587898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokine expression in murine cornea tissue during recurrent herpetic stromal keratitis].
    Xia LK; Zhang JS; Chen XL; Wang AY
    Zhonghua Yan Ke Za Zhi; 2005 May; 41(5):403-8. PubMed ID: 15938803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine expression in murine corneas during recurrent herpetic stromal keratitis.
    Keadle TL; Usui N; Laycock KA; Kumano Y; Pepose JS; Stuart PM
    Ocul Immunol Inflamm; 2001 Sep; 9(3):193-205. PubMed ID: 11815888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapy.
    Staats HF; Lausch RN
    J Immunol; 1993 Jul; 151(1):277-83. PubMed ID: 8392096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of macrophages in restricting herpes simplex virus type 1 growth after ocular infection.
    Cheng H; Tumpey TM; Staats HF; van Rooijen N; Oakes JE; Lausch RN
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1402-9. PubMed ID: 10798656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.